The article analyzes that Eli Lilly's stock price recently reached $1280 per share, with its last stock split occurring nearly 30 years ago in October 1997. Although stock splits typically do not change the total value of a stock, they can be meaningful when the share price becomes unaffordable for average investors. Additionally, Eli Lilly's second-quarter revenue increased by 48% year-over-year, primarily driven by strong sales of Mounjaro and Zepbound. The company currently has a price-to-earnings ratio of 41, which is below its five-year average of 58.